CA1287802C - Pharmaceutical formulation containing cimetidine - Google Patents

Pharmaceutical formulation containing cimetidine

Info

Publication number
CA1287802C
CA1287802C CA000543046A CA543046A CA1287802C CA 1287802 C CA1287802 C CA 1287802C CA 000543046 A CA000543046 A CA 000543046A CA 543046 A CA543046 A CA 543046A CA 1287802 C CA1287802 C CA 1287802C
Authority
CA
Canada
Prior art keywords
cimetidine
composition according
mpa
polymorphic
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000543046A
Other languages
English (en)
French (fr)
Inventor
Brian Anthony Carlin
John Norman Healey
Graham Stanley Leonard
Geoffrey David Tovey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline & French Laboratories Ltd
Original Assignee
Smith Kline & French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline & French Laboratories Ltd filed Critical Smith Kline & French Laboratories Ltd
Application granted granted Critical
Publication of CA1287802C publication Critical patent/CA1287802C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA000543046A 1986-08-01 1987-07-27 Pharmaceutical formulation containing cimetidine Expired - Lifetime CA1287802C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8618847 1986-08-01
GB868618847A GB8618847D0 (en) 1986-08-01 1986-08-01 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
CA1287802C true CA1287802C (en) 1991-08-20

Family

ID=10602097

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000543046A Expired - Lifetime CA1287802C (en) 1986-08-01 1987-07-27 Pharmaceutical formulation containing cimetidine

Country Status (22)

Country Link
US (1) US4996222A (enExample)
EP (1) EP0257823B1 (enExample)
JP (1) JPH0643304B2 (enExample)
KR (1) KR960012397B1 (enExample)
CN (1) CN1024497C (enExample)
AU (1) AU601206B2 (enExample)
CA (1) CA1287802C (enExample)
DE (1) DE3778795D1 (enExample)
DK (1) DK149988D0 (enExample)
EG (1) EG18388A (enExample)
ES (1) ES2037086T3 (enExample)
GB (1) GB8618847D0 (enExample)
GR (1) GR3005298T3 (enExample)
HU (1) HU205853B (enExample)
IE (1) IE60759B1 (enExample)
IL (1) IL83349A (enExample)
MY (1) MY100998A (enExample)
PH (1) PH23505A (enExample)
PT (1) PT85468B (enExample)
WO (1) WO1988000825A1 (enExample)
ZA (1) ZA875631B (enExample)
ZW (1) ZW13587A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU196775B (en) * 1986-08-05 1989-01-30 Richter Gedeon Vegyeszet Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
JPH0482832A (ja) * 1988-09-20 1992-03-16 Glaxo Group Ltd 医薬組成物
GB9127150D0 (en) * 1991-12-20 1992-02-19 Smithkline Beecham Plc Novel treatment
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
FI941777L (fi) * 1993-04-16 1994-10-17 Mcneil Ppc Inc Vesipitoinen farmaseuttinen suspensio ja menetelmä sen valmistamiseksi
WO1996003976A1 (en) * 1994-08-01 1996-02-15 Kv Pharmaceutical Corporation Tastemasked liquid pharmaceutical delivery system
GB9504599D0 (en) * 1995-03-03 1995-04-26 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
GB2298365B (en) * 1995-03-03 1997-05-07 Reckitt & Colmann Prod Ltd A liquid pharmaceutical composition alginate and potassium bicarbonate
PL194696B1 (pl) * 1997-04-30 2007-06-29 Reckitt Benckiser Healthcare Kompozycja w stałej postaci dawkowania zawierająca alginiany
GB9708772D0 (en) * 1997-04-30 1997-06-25 Reckitt & Colmann Prod Ltd Organic compositions
IN186245B (enExample) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US6515008B1 (en) * 2000-05-04 2003-02-04 Smithkline Beecham Corporation Formulation
DE10224086A1 (de) * 2002-05-31 2003-12-11 Bayer Ag Pharmazeutische Zubereitungen zur oralen Anwendung enthaltend wirkstoffbeladene Ionentauscherharze sowie strukturviskose Gelbildner als Verdicker
US6930119B2 (en) * 2002-07-17 2005-08-16 Reliant Pharmaceuticals, Inc. Liquid pharmaceutical composition
EP1603579A4 (en) * 2003-03-10 2006-06-14 Univ Michigan COMPOSITIONS AND METHODS OF USE OF ALGINATE DURAL SEALANTS
WO2006048426A1 (en) * 2004-11-02 2006-05-11 Purac Biochem B.V. Method for stabilizing and preventing coagulation of proteins in milk
US20060094760A1 (en) * 2004-11-04 2006-05-04 Fawzy Abdel A Composition, system and method of treatment of gastrointestinal disorders with nizatidine oral solution
ATE396710T1 (de) * 2005-07-19 2008-06-15 Ethypharm Sa Gastroretentive zusammensetzungen und verfahren zur herstellung
FR2911506B1 (fr) * 2007-01-18 2009-07-03 Ceva Sante Animale Sa Compositions pharmaceutiques destinees a une administration par voie orale sous forme de suspensions aqueuses stabilisees
US8999395B2 (en) * 2007-02-09 2015-04-07 Ceva Sante Animale Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions
CN102612359A (zh) * 2009-09-10 2012-07-25 拜欧波尔特拉及正大有限公司 醋酸艾司利卡西平的口服混悬剂制剂
WO2018075801A1 (en) * 2016-10-19 2018-04-26 Signpath Pharma, Inc. Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
GB201918617D0 (en) * 2019-12-17 2020-01-29 Reckitt Benckiser Health Ltd Personal lubricant composition
WO2024231881A2 (en) * 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56104868A (en) * 1980-01-24 1981-08-20 Fujimoto Seiyaku Kk Conversion between polymorphous crystals of cimetidine
HU185457B (en) * 1981-09-25 1985-02-28 Richter Gedeon Vegyeszet Process for preparating cimetidine-z
CA1239349A (en) * 1983-10-10 1988-07-19 Eberhard F. Gottwald Pharmaceutical composition containing cimetidine

Also Published As

Publication number Publication date
PT85468A (en) 1987-08-01
HU205853B (en) 1992-07-28
KR960012397B1 (ko) 1996-09-20
JPH0643304B2 (ja) 1994-06-08
MY100998A (en) 1991-06-29
AU601206B2 (en) 1990-09-06
DE3778795D1 (de) 1992-06-11
GB8618847D0 (en) 1986-09-10
JPH01500434A (ja) 1989-02-16
ZA875631B (en) 1989-03-29
KR880701551A (ko) 1988-11-03
DK149988A (da) 1988-03-18
EP0257823A1 (en) 1988-03-02
ZW13587A1 (en) 1989-02-15
IL83349A (en) 1992-03-29
EG18388A (en) 1992-10-30
CN87105387A (zh) 1988-02-17
ES2037086T3 (es) 1993-06-16
HUT46541A (en) 1988-11-28
DK149988D0 (da) 1988-03-18
IE60759B1 (en) 1994-08-10
PT85468B (pt) 1990-06-29
IE872077L (en) 1988-02-01
EP0257823B1 (en) 1992-05-06
AU7756487A (en) 1988-02-24
PH23505A (en) 1989-08-16
GR3005298T3 (enExample) 1993-05-24
CN1024497C (zh) 1994-05-18
WO1988000825A1 (en) 1988-02-11
US4996222A (en) 1991-02-26

Similar Documents

Publication Publication Date Title
EP0257823B1 (en) Pharmaceutical formulations
EP0138540B1 (en) Pharmaceutical compositions
JP2847134B2 (ja) 経口投与用イブプロフェン組成物
US4684666A (en) Stabilized liquid analgesic compositions
US4788220A (en) Pediatric ibuprofen compositions
JP3631782B2 (ja) ウルソデオキシコール酸を含む液体投与形態の薬剤
KR100477782B1 (ko) 지프라시돈 현탁액
EP1452169B1 (en) Aqueous base liquid pharmaceutical compositions in suspension form for the oral administration of ibuprofen
US6515008B1 (en) Formulation
KR19980701912A (ko) 트리메부틴을 함유하는 신규 제약 조성물 및 그 제조 방법
US20070134323A1 (en) Ziprasidone suspension

Legal Events

Date Code Title Description
MKEX Expiry